Aspen Pharmacare Holdings Stock EBITDA
| APN Stock | 17,904 111.00 0.62% |
Aspen Pharmacare Holdings fundamentals help investors to digest information that contributes to Aspen Pharmacare's financial success or failures. It also enables traders to predict the movement of Aspen Stock. The fundamental analysis module provides a way to measure Aspen Pharmacare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aspen Pharmacare stock.
Aspen |
Aspen Pharmacare Holdings Company EBITDA Analysis
Aspen Pharmacare's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Aspen Pharmacare EBITDA | 10.61 B |
Most of Aspen Pharmacare's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aspen Pharmacare Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Aspen Pharmacare Holdings reported earnings before interest,tax, depreciation and amortization of 10.61 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The ebitda for all South Africa stocks is 172.21% lower than that of the firm.
Aspen EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aspen Pharmacare's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aspen Pharmacare could also be used in its relative valuation, which is a method of valuing Aspen Pharmacare by comparing valuation metrics of similar companies.Aspen Pharmacare is currently under evaluation in ebitda category among its peers.
Aspen Fundamentals
| Return On Equity | 0.095 | |||
| Return On Asset | 0.0499 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 78.78 B | |||
| Shares Outstanding | 444.95 M | |||
| Shares Owned By Insiders | 19.32 % | |||
| Shares Owned By Institutions | 60.77 % | |||
| Price To Book | 0.88 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 38.61 B | |||
| Gross Profit | 18.29 B | |||
| EBITDA | 10.61 B | |||
| Net Income | 8.67 B | |||
| Total Debt | 105 M | |||
| Book Value Per Share | 159.44 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 14.32 X | |||
| Target Price | 175.61 | |||
| Number Of Employees | 8.58 K | |||
| Beta | 0.62 | |||
| Market Capitalization | 98.32 B | |||
| Total Asset | 111.38 B | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 111.38 B | |||
| Last Dividend Paid | 3.26 |
About Aspen Pharmacare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aspen Pharmacare Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aspen Pharmacare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aspen Pharmacare Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Aspen Stock
Aspen Pharmacare financial ratios help investors to determine whether Aspen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aspen with respect to the benefits of owning Aspen Pharmacare security.